BioMed X and AbbVie Start New Research Project in the USA

NEW HAVEN, CT, Nov 1, 2023 – (ACN Newswire) – BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA. The project aims to generate an organotypic human arterial model with sufficient complexity to recapitulate key characteristics of chronic autoimmune disease onset, progression, and resolution, with the long-term goal of advancing patient treatment.

Dr. Alicia Cutler is the Group Leader of the “Complex Human Ex Vivo Models of Tissue Inflammation” project. Before accepting this position at BioMed X, Alicia was a Research Associate in the Department of Molecular, Cell, and Developmental Biology at the University of Colorado Boulder, USA. “My initial training in biochemistry and stem cell biology positioned me to expand my research interests towards tissue engineering and bioprinting. I am very excited about this opportunity to start a new research group on this topic with the support of BioMed X and AbbVie,” explains Alicia.

The new BioMed X Institute is located in New Haven, CT, in the Elm City Bioscience Center, neighboring Yale University, and will be managed by Mark Johnston, an experienced biotech CEO and entrepreneur. “Alicia was the winner of a competitive boot camp we conducted with our partners at AbbVie, following BioMed X’s unique crowdsourcing model. I am thrilled she accepted to be our first BioMed X US Group Leader,” says Mark Johnston, Chief Executive Officer of BioMed X USA.

This is already the second research collaboration between BioMed X and AbbVie. Dr. Christian Tidona, Founder and Managing Director of the BioMed X Institute, explains: “After 10 years of success stories at our institute in Heidelberg, Germany, we have decided to extend our operations overseas. Our first project with AbbVie in Heidelberg was successfully completed in 2019, focusing on Tau-mediated neurodegeneration in Alzheimer’s disease. We are grateful that AbbVie has agreed to partner with us again for our first project on US territory,” adds Tidona.

“We are pleased to expand our collaboration with BioMed X to the US and continue the work to enhance our understanding of human disease biology. This is a unique opportunity to create the complex in vitro model systems needed to advance the field of immunology research and beyond,” said Dr. Timothy Radstake, Vice President & Global Head, Immunology Discovery Research at AbbVie.

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian, Recruiting & Communications Manager, fbc@bio.mx +49 6221 426 11 706

Acrometa to Focus on Laboratory Construction and Co-Working Laboratory Space Business

SINGAPORE, Oct 31, 2023 – (ACN Newswire) – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that the Board of Directors of the Company’s indirect subsidiary, Neo Tiew Power Pte. Ltd. (“NTP”), had on 27 October 2023 initiated the process to place NTP under Creditors’ Voluntary Liquidation ( “CVL”). NTP is a wholly-owned subsidiary of Acropower Pte. Ltd., which the Company has an effective interest of 56% in.

NTP was incorporated in February 2020 to produce renewable energy by converting biomass poultry waste into green electricity by the process of pyrolysis. However, due to the Covid-19 pandemic and changes to regulations for the safe handling of potentially dangerous animal waste products, NTP has not been able to commence operations.

The Group had extended significant loans to NTP and has decided it cannot continue supporting NTP. The directors of NTP had on 27 October 2023 resolved to place NTP in Provisional Liquidation, pending its eventual liquidation. Insolvency Practitioners from Alternative Advisors Pte Ltd were appointed as Provisional Liquidators. This decision arises from the inability of NTP to continue its regular business operations by reason of their liabilities.

Mr Lim Say Chin, CEO of AcroMeta Group said, “Conversion of poultry waste to green electricity is a fundamentally promising business. However, the Covid-19 pandemic’s impact on construction as well as changes in regulations for the safe handling of animal waste products meant that the project would continue to require financial support and affect the Group’s allocation of resources.”

Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said, “The Board’s decision for the voluntary liquidation of NTP by Acropower reflects our current focus on expanding the laboratory construction and co-working laboratory space businesses, both of which are currently cash flow positive and show a promising future with an encouraging flow of business opportunities and projects in the last twelve months.”

In August 2023, the Group’s wholly-owned subsidiary Acromec Engineers Pte Ltd (“Acromec”) was awarded a S$19 million contract for the design and construction of a 1,500 sqm high containment biosafety level research laboratory. In October 2023, the Group’s 70% owned subsidiary company Life Science Incubator Pte Ltd (“Life Science Incubator” or “LSI”) entered into a Management Agreement (the “MA”) with HB Universal Pte Ltd, a subsidiary of Mainboard-listed Ho Bee Land Limited, to operate and manage a co-working laboratory space at Elementum, One-North, a building in the heart of Singapore’s biomedical industry district.

About ACROMETA Group Limited (SGX Stock Code:43F)

ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.

The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.

Media and Analysts Contact:

ACROMETA Group Limited, Ms. Cheah Lai Min, Chief Financial Officer, Tel: +65 6415 0574, Email: laimin.cheah@acrometa.com

Waterbrooks Consultants Pte Ltd, Mr. Wayne Koo, Tel: +65 6958 8008 / +65 9338 8166, Email: wayne.koo@waterbrooks.com.sg, Email: query@waterbrooks.com.sg

This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.

NAM aspires to be leader in manufacturing, import and distribution of medical instruments and sterile medical equipment in Thailand

BANGKOK, Oct 31, 2023 – (ACN Newswire) – Namwiwat Medical Corporation Public Company Limited (NAM) is confident that investors will respond well to the first day of trading of the Company’s shares on the Stock Exchange of Thailand (SET). The Company aspires to become a leader in the manufacturing, import, and distribution of medical instruments and sterile medical equipment in Thailand. Moreover, Namwiwat is striving to foster growth both domestically and abroad to actively drive Thailand’s medical device industry to global level, while being ready to reinforce business potential after major national corporations took up shares in the Company to together strengthen the business.

Mr. Viroj Chaiturdkiet, Chief Executive Officer of Namwiwat Medical Corporation Public Company Limited (Company or NAM), revealed that the Company has listed its shares for first-day trading on October 31, 2023 on the Stock Exchange of Thailand (SET), under the “Consumer Products” industry group and “Personal Products & Pharmaceuticals” sector with the trading abbreviation “NAM”. The Company firmly believes in the potential of its operation with more than 50 years of experience and expertise in the industry, and the accumulation of knowledge and knowhow, coupled with the introduction of new innovations in the production of medical instruments and equipment. These positive aspects will definitely make NAM a new IPO stock that will attract investors.

The Company plans to foster continuous growth by investing to increase competitiveness, as the demand for higher medical standards is currently on the increase, especially in regard to decontamination, disinfection and sterilization for which the equipment must be absolutely safe for reuse. Therefore, it is extremely important to heighten medical standards because the process to reduce the risk of contamination from outside is crucial. As a result, the medical industry, from large hospitals to nursing homes, have made continuous adjustments and paying closer attention to improving the standards of cleanliness and sterilization, thus, leading to increased demand for the cleaning and disinfecting of medical equipment.

Therefore, the Company has planned to use part of the capital raised from the fundraising to expand the new factory to increase production capacity of both medical equipment and consumable medical products to support the increasing demand for medical equipment products, as well as to support the manufacturing of new products that the Company will develop with partners in the future. In addition, the Company plans to invest in the development of medical equipment research and development center with the focus on developing products that meet the specific needs of hospitals at all levels, and passing on equivalent standards of cleanliness. It needs to be stressed that research, studies and data collection in various aspects form important steps in product research and development. Therefore, the Company plans to increase manpower in the fields of research & development, engineering and chemistry, while also adding or expanding floor space, and installing more equipment, instruments and machines. Also essential is the enhancement of software that requires additional programs in the areas of drafting, design, and analysis to expedite more operational convenience and suitability. These plans are expected to be put in place in the 2nd to 3rd quarters of 2024.

In addition, the Company is drawing up a strategic plan to create growth through expanding businesses related to medical equipment, cleaning, disinfection and sterilization and/or related businesses, to increase competitiveness and increase value for the Company in a consolidated manner. Also, the Company will focus more on expanding its businesses abroad to create a solid foundation to support growth and to drive Thailand’s medical equipment industry to global level in the future.

Mr. Varah Sucharitakul, Chairman of Finansa Securities Limited, as the Lead Underwriter, said that the fundraising of Namwiwat Medical Corporation Plc. is an important step that will help drive NAM to grow into a world-class medical instrument and equipment brand. And with the Company’s potential and impressive business expansion plan, many major national corporations have decided to become partners, including Innobic LL Holding Company Limited (a PTT Public Company Limited subsidiary), Innosprout Holding Company (a Pruksa Holding Public Company Limited subsidiary), and WHA Venture Holding Company Limited (a WHA Corporation Public Company Limited subsidiary), so as to join forces in doing business together. This fact should allow investors and shareholders to see the potential of the Company’s becoming a leader in the manufacturing and distribution of sterile medical instruments and equipment in Thailand while being ready to build on sustainable strength.

Mr. Vorachart Tuaycharoen, Managing Director of Finnex Advisory Co., Ltd., , as a financial advisor, said NAM is considered one of the leaders in the manufacturing and distribution of sterile medical instruments and equipment in Thailand that possesses a strong research and development team enabling the Company to create products and services and to develop new innovations, as well as expanding distribution channels both domestically and abroad. It is also significant that NAM has a group of strong allies to help reinforce the business. Thus, this is leading to an important opportunity for NAM to research and develop new products in order to better meet the needs of customers.

Mr. Kumpon Suangburanakul, Chief of Corporate Finance of Thanachart Securities Public Company Limited, as a financial advisor, said NAM has laid out strategies to maintain continuous growth, especially to cater to government hospitals as a customer group. The Company also plans to increase customers in the private hospital group, clinics or other public health organizations. As such, there are still many opportunities for potential customers to purchase the Company’s products or services, particularly with the strength in offering products and providing integrated services from manufacturing, importing, and distributing medical instruments and equipment as well as various related services. Also, there have been advancement in research and development to the point of registering own patents and the Company has also been registered as being a member of the country’s medical innovation group through the application of modern manufacturing technology in order to achieve high quality and internationally accepted standards.

Press release by MT Multimedia Company Limited (For Namwiwat Medical Corporation Plc.)
For additional information: Yuttachai Praikanahok (Tle)
Tel: +66 (0)91 736 2866; Email: Yuttachai.p@mtmultimedia.com

Airlangga University Professor develops New Epilepsy Treatment

Surabaya, East Java, Indonesia, Oct 30, 2023 – (ACN Newswire) – A medical professor at Airlangga University, Prastiya Indra Gunawan, has developed a new epilepsy treatment method that involves administering midazolam intramuscularly and intranasally.

Airlangga University professor Prastiya Indra Gunawan has devised a new treatment method that involves providing midazolam intramuscularly and intranasally to epilepsy patients. — Airlangga University professor Prastiya Indra Gunawan has devised a new treatment method for epilepsy patients that involves providing midazolam intramuscularly and intranasally. [Image: Airlannga]

The new method can be a solution for treating epilepsy, for which electroencephalography (EGG) examinations have been used so far. The results of those examinations are often misinterpreted, causing excessive diagnosis of epilepsy and prolonged use of antiepileptic drugs, which is not necessary.

“Intramuscular midazolam is able to stop seizures within 45 seconds, while intranasal midazolam is able to stop seizures within 42 seconds. This is different from rectal diazepam, which takes 180 seconds,” Professor Gunawan, a pediatrician from Airlangga University, said.

He has received recognition as a pioneer in changing the procedures for handling childhood seizures and has obtained intellectual property rights (IPR). Gunawan officially obtained the IPR in 2019 and 2021 based on the research and publications he carried out in 2015 and 2016.

Gunawan has made other advances in the field, having diagnosed epilepsy in patients who were drug resistant and had been diagnosed with other causes.

“In terms of diagnostics, the diagnosed cause was infection, the diagnosed cause was head trauma, but now, we are also developing diagnosis to include autoimmune. Indeed, we have been able to diagnose patients who have epilepsy with a resistance to drugs. We continued to look for it, and the cause is autoimmune,” he said.

Even after the cause has been identified, seizures that are resistant to adequate medication are still difficult to treat. In this case, according to Gunawan, surgery can be an alternative.

Unfortunately, not all health facilities can perform epilepsy surgery. With the current technological advances, Gunawan said it is necessary to build a comprehensive epilepsy service center, an idea which he shared at the N-20 Conference during the G20 Summit in Bali in 2022.

“The key to this epilepsy center is to assemble the right team with the right people who have the same approach to dealing with epilepsy,” he said. “The epilepsy center will not only be for treatment but will help address social stigma. Many people with epilepsy feel isolated by their environment, hampered in their careers, and feel they have failed in their home life.”

With the establishment of the epilepsy center, Gunawan said he hopes that people with epilepsy will not only receive healthcare, but also see improvements in their social life. He also invited everyone to work together to care for epilepsy sufferers.

Reporter: Yashinta Difa Pramudyani
Editor: Tia Mutiasari
Copyright (c) ANTARA 2023

EW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural Medicine

LONDON, Oct 27, 2023 – (ACN Newswire) – EW Healthcare Partners announced that it has acquired a c. 25% minority stake in Boiron Developpement, an entity formed for the purposes of launching a tender offer for the Boiron Group, in partnership with the Boiron Family, at a c. €875 million enterprise value. As part of this transaction, the Boiron family has transferred its 70% stake in the Boiron Group to Boiron Developpement, together with the Boiron employee fund for c. 5% of the capital.

Boiron is a French pharmaceutical company focused on natural medicine, founded in 1932 by pharmacists Jean and Henri Boiron. The company is built around homeopathy and has spearheaded the industry’s global development.

Boiron today is the global market leader in homeopathy and a leading global player in natural medicines, with 2022 revenues of €534M. The company offers a diversified portfolio of natural, innovative, science-based, and personalized pharmaceutical products. Over 50% of Boiron’s sales are realized outside of France. Boiron benefits from an integrated value chain from registration to distribution, including in-house manufacturing, with the company currently present in 50 countries globally through 23 subsidiaries and 30 distributors. Boiron has also established a strong footprint in the U.S. with €120M in U.S. revenue, with a large portion of products sold through the e-commerce channel.

EW Healthcare Partners is excited to partner with the Boiron family to help further accelerate the company’s growth, by expanding the company’s offering into additional healthcare verticals and capitalising on the existing platform to launch additional products, in particular in the U.S.

About EW Healthcare Partners (“EW”)

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston. https://www.ewhealthcare.com

Contact Information

Anne DeMaret, Investor Relations, ademaret@ewhealthcare.com (281) 528-1956

Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US

Adelaide, Australia & North Carolina, USA, Oct 19, 2023 – (ACN Newswire) – Avance Clinical, the Australian and North American market-leading CRO for biotechs, was asked to present their GlobalReady drug development solution to more than 45 Korean biotechs and pharmaceutical companies in Seoul, Korea last week as part of a special symposium at KoNECT Korea Conference.

Dt & SanoMedics Chairman, Charles Park (Park, Chae Gyoo) and Avance Clinical CEO Yvonne Lungershausen co-hosting the Global Clinical Trial Strategy Symposium in Korea last week.

Avance Clinical’s Korean CRO partner Dt & SanoMedics initiated the Global Clinical Trial Strategy Symposium and invited Avance Clinical to co-host.

The Avance Clinical team, including CEO Yvonne Lungershausen, and Vice President, Commercial Business Development, Liahna Toy discussed drug development options including conducting clinical trials across South Korea, Australia, New Zealand, and the United States to support fast tracking clinical trial development programs.

Yvonne Lungershausen said Avance Clinical offers two critical solutions for biotechs.

“Avance Clinical in Australia can maximise the 43.5% rebate on clinical trial spend, and in the United States can provide high quality trials following the FDA pathway. Both approaches were received as attractive propositions for biotechs wanting to maximise their data captured and conserve funding,” she said.

“Our Avance Clinical teams in Australia and the United States offer world-class quality data and cultural alignment for Korean biotech clients designed to make their drug development programs seamless and successful.”

“Avance Clinical’s study data is accepted by all the main regulatory authorities including the MFDS and FDA; and conversely the Therapeutic Goods Administration (TGA) in Australia recognises data generated in Korea.”

Yvonne Lungershausen thanked Korean CRO partner Dt & SanoMedics for arranging the Global Clinical Trial Strategy Symposium.

“This was an impressive group of biopharma companies and we are extremely excited to be part of their clinical program as they expand to the United States.”

“Thank you to Chairman of the Dt&C group, Charles Park and Yujin Lee, Vice-President of Dt & SanoMedics, and the entire team for welcoming and hosting Avance Clinical in South Korea.”

Dt & SanoMedics VP Yujin Lee said the partnership with Avance Clinical has been further strengthened with the team providing valuable international drug development strategies for the Korean biotech community.

“We are pleased to introduce the Avance Clinical team because we know they stand for quality. Importantly, they have the experience and track-record especially in the United States which is where most biotechs will be conducting their later phase trials.”

“We believe this has been an important visit which has enabled us to enhance our partnership and actively help Korean companies enter the US and Australian pharmaceutical markets,” she said.

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognised for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

www.avancecro.com

Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com

Discipline Industries Unveils Cutting-Edge Product Line: NAC, NMN and Taurine for Optimal Health and Wellness

SYDNEY, AU, Oct 18, 2023 – (ACN Newswire) – Discipline Industries, a leading innovator in the health and wellness industry, is proud to announce the launch of its new product line featuring N-acetylcysteine (NAC), Nicotinamide Mononucleotide (NMN), and Taurine. This revolutionary product line is poised to revolutionize the way individuals approach their health and well-being.

In an era where the pursuit of a healthier and more vibrant life has become a top priority for many, Discipline Industries is at the forefront, offering science-backed solutions that cater to a wide range of wellness needs.

NAC, NMN, and Taurine are three distinct supplements that have gained significant attention in the world of health and wellness. These products have been meticulously formulated by Discipline Industries to deliver the highest quality and purity, ensuring customers have access to the very best supplements on the market.

N-acetylcysteine (NAC) is a potent antioxidant that plays a crucial role in supporting respiratory health, liver function, and detoxification. NMN is an essential precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and the aging process. Taurine, on the other hand, is known for its role in supporting cardiovascular health, cognitive function, and overall vitality.

Discipline Industries‘ Chief Marketing Officer Suman Sandhu expressed enthusiasm about the new product line, stating, “At Discipline Industries, we’re committed to delivering products that enable individuals to take control of their health and achieve their wellness goals. Our NAC, NMN, and Taurine supplements are meticulously crafted to provide the highest-quality ingredients, ensuring that our customers can achieve optimal health and vitality.”

Discipline Industries’ NAC, NMN, and Taurine products offer several key benefits to consumers:

Superior Quality: All products are manufactured using state-of-the-art processes and adhere to strict quality control standards.

Scientifically Formulated: The supplements are designed based on the latest scientific research to provide the most effective results.

Comprehensive Health Support: These supplements offer a wide range of potential benefits for various aspects of health and wellness.

Transparency and Trust: Discipline Industries is committed to transparency, ensuring that consumers have complete access to information about the products they are using.

Discipline Industries’ new product line is now available for purchase on the company’s official website https://Discipline.Industries and through authorized retail partners. The company encourages customers to explore the range of offerings and take the first step toward achieving their health and wellness goals.

For further information about Discipline Industries and its new NAC, NMN, and Taurine product line, please visit https://Discipline.Industries or contact Suman Sandhu at marketing@discipline.rocks.

About Discipline Industries:

Discipline Industries is a forward-thinking company dedicated to providing innovative solutions in the health and wellness sector. With a strong commitment to quality and customer satisfaction, Discipline Industries produces cutting-edge products that empower individuals to take control of their health and well-being.

Contact Information

Suman Sandhu, Marketing Manager, sales@discipline.rocks, +61731068912

Diet Choice Could Help Solve the Climate Crisis, Major New Study Finds

WINCHESTER, ENGLAND, Oct 17, 2023 – (ACN Newswire) – In a major new study, prominent scientists from around the world have developed a new strategy for addressing climate change. The study “Proposed solutions to anthropogenic climate change: a systematic literature review and a new way forward,” published in leading scientific journal Heliyon, demonstrates that climate change solutions must include a shift to a more fundamentally plant-based diet and a global phaseout of industrialized animal farming. The authors also recommend the adoption of an “All Life” approach that recognizes the profound interconnectedness of all life on Earth and a global standardization of climate change metrics.

Solutions to anthropogenic climate change

Our planet is in a state of emergency and we only have a short window of time (7-8 years) to enact meaningful change to prevent an eventual global climate crisis that will impact each and every one of the Earth’s inhabitants. To achieve this monumental task in such a short space of time, human activities cannot continue on a “business-as-usual” basis. And the data clearly indicate that we will not succeed without changes in the way that we eat and produce food.

“We must recognize that by solely focusing on reducing greenhouse gas emissions to limit global warming, we are treating the symptom of the cause, and the cause is major global unsustainability. To achieve long-lasting transformative change, which will benefit current and future generations (and save our planet), we need to change our mindset and behavior as individuals, communities, businesses, governments, and global citizens,” says lead author Svetlana V. Feigin, Ph.D.

“Animal agriculture is not necessary (nor sustainable) to feed the growing global population,” the authors contend. Regarding the phaseout of industrialized animal farming, the authors propose “ending government subsidies for animal-based meat, dairy and eggs, and initiating taxes on such products to account for the wide-ranging externalized costs that are currently passed on to taxpayers, governments, societies and future generations.” Other actions include “more stringent legislation on animal welfare standards and divestment in industrialized animal agriculture.”

Also in the study, the authors introduce and discuss the concept of an “All Life” approach. An “All Life” approach emphasizes the protection of the “oneness of life” (humans, animals, plants, the entire planet), and emphasizes that our health, and the health of our planet, are intimately intertwined with the health and wellbeing of all living beings. It emphasizes the interdependence and protection of all life forms and shifts away from a human-centric paradigm to an Earth-centric paradigm.

We are running out of time to alter our current trajectory, and thus to enact meaningful change that will have a profound impact upon the future wellbeing of the planet and all of its inhabitants. Failure to act will ultimately result in a scenario of irreversible climate change, with widespread famine and disease, global devastation, climate refugees, and warfare following resource scarcity.

Contact Information

Andrew Knight, Veterinary Professor of Animal Welfare, andrew.knight@winchester.ac.uk

Svetlana Feigin, Dr drsvetlanafeigin@gmail.com, (+64) 21 1368549 (New Zealand)

An Urgent Call to Scale-Up Access to Healthy Diets for the Most Vulnerable

THE HAGUE, NETHERLANDS, Oct 17, 2023 – (ACN Newswire) – The world is facing unprecedented global food and nutrition crises because of soaring food prices, regional conflicts, more frequent and intense climate-related disasters, and the lasting economic and societal effects of COVID-19. The near- and long-term adverse impacts of these compounding challenges threaten the health and future of vulnerable communities and are taking a particularly heavy toll on mothers and young children. The Global Alliance for Improved Nutrition, the Micronutrient Forum, Wageningen University & Research and Scaling Up Nutrition (SUN) will be present at the Micronutrient Forum’s Sixth Global Conference.

The Micronutrient Forum’s Sixth Global Conference, Nutrition for Resilience, is a watershed moment for the global nutrition community. It will bring together an estimated 3,000 experts, leaders, and advocates from diverse fields to have the vital discussions needed to align priorities and action plans, as well as prioritize investments in nutrition.

Saskia Osendarp, Executive Director of the Micronutrient Forum, said, “This conference will be the catalyst we need for robust scientific discussions and policy dialogues. We have no more time. We must foster a renewed sense of urgency to facilitate alignment between nutrition and resilience agendas across sectors and make tangible progress towards global development goals.”

In a complex global landscape, the conference will explore the intricate link between micronutrient status and resilience, aiming to identify specific, concrete, actions that can support the most vulnerable, particularly women and children.

Lawrence Haddad, Executive Director of the Global Alliance for Improved Nutrition (GAIN), said, “We are convening at a critical time in history when people across the world are increasingly experiencing economic, conflict and environmental shocks. We urgently need to create food systems that are more diverse in what foods are grown, where they are grown, how they are grown, and in the foods consumed. Diversity is the antidote to risk and is key to ensuring the nutrition status of vulnerable families is more resilient to the increased frequency and intensity of shocks we are witnessing today — and which we will continue to see in the next 10 years.”

Sjoukje Heimovaara, President of Wageningen University & Research, said, “Fresh insights from scientists, policymakers, and practitioners are very much needed to increase resilience through healthier diets. The Micronutrient Forum helps to shape and sharpen these insights, so all involved can accelerate action.”

Afshan Khan, Coordinator of Scaling Up Nutrition (SUN), said, “This is an invaluable opportunity for the SUN Movement and the governments implementing national nutrition plans to engage with academia, practitioners, civil society and business at the global level and share initiatives for improved nutrition outcomes. The micronutrient forum can propel further action and lead to financing for nutrition that supports both people and planet.”

In keeping with the Micronutrient Forum’s commitment to global knowledge equity, this conference promises to be the most accessible yet. It will provide a robust and interactive online experience alongside the in-person programme. All plenary, sponsored and concurrent sessions will be live-streamed, ensuring people can participate from anywhere in the world.

Contact Information:

Ivan Simeonov isimeonov@kenes.com

Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China’s Top 100 Pharmaceutical Innovative Enterprises in 2023

Hong Kong, Oct 13, 2023 – (ACN Newswire) – Sihuan Pharmaceutical Holdings Group Ltd. (the “Company” or “Sihuan Pharmaceutical”, together with its subsidiaries, the “Group”, HKEX stock code: 0460) is pleased to announce that, Huisheng Biopharmaceutical, Co., Ltd. (“Huisheng Biopharmaceutical”), a non-wholly owned subsidiary of the Group, was selected as one of the first echelon of enterprises in The list of China’s Top 100 Pharmaceutical Innovative Enterprises in 2023.

The list of China’s Top 100 Pharmaceutical Innovative Enterprises in 2023 was released recently. The list is created by E Medicine Manager based on the patent data of Derwent Innovation of Clarivate Analytics and Cortellis(TM) competitive intelligence and clinical trial data, screening, integrating and analyzing the data through the selection system of “three dimensions and four indicators”. The list aims to explore innovation power for the industry, disseminate innovative experiences, and deeply analyze the innovation ability and sustainability of China’s pharmaceutical industry.

In 2018, an authoritative data released that China’s contribution to global pharmaceutical research and development increased to 4%-8%, second only to the United States and Japan, and entered the second echelon, indicating that China’s pharmaceutical innovation has entered the golden age.

Taking this as an opportunity, E Medicine Manager has selected the “China’s Top 100 Pharmaceutical Innovative Enterprises” representing the innovation strength of China’s pharmaceutical industry every year since 2019 through model building, data collection and sorting, starting from the current situation of pharmaceutical innovation, with the enterprise as the main body and the hard data as the support, evaluating the enterprises based on four indicators, namely the number of authorized patents, the total number of patents applied, the number of clinical trials and the number of innovative drugs approved and launched through the three dimensions of innovation foundation, innovation process and innovation achievements, so far this selection has been conducted for 5 years.

The Top 100 innovative enterprises are the first-tier enterprises that represent the pharmaceutical innovation capability of China and the core competitiveness of the industry, the backbone to promote the transformation and upgrading of China’s pharmaceutical industry. The listing of Sihuan Pharmaceutical as one of the first echelon of enterprises is the recognition of the Company’s innovation strength, technical reserve and sustainable innovation ability, and the affirmation of the Company’s outstanding contribution in the development of the pharmaceutical industry.

This year, Sihuan Pharmaceutical and its subsidiaries have received good news constantly. A number of its products have been approved for marketing, and clinical study has made significant progress and the research results have been selected into authoritative international academic conferences. In the future, we hope that Sihuan Pharmaceutical can continuously innovate and develop more and better Chinese drugs, promoting the development and growth of the pharmaceutical industry and serving the benefit of people’s health.

Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX: 0460) is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with a leading independent production, and R&D technology platform, a rich global product pipeline and a mature and excellent sales system. Focusing on high-growth therapeutic areas such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine and industrial hemp, it adheres to its overall strategic objective of “Adhering to the full-speed promotion of a two-wheeled strategy of Sihuan medical aesthetics and biopharmaceuticals” to build a leading medical aesthetics and biopharmaceutical company in China.

For more information about Sihuan Pharmaceutical, please visit the Company’s website at https://www.sihuanpharm.com/